Gary Phillips, an experienced pharma executive and practicing physician, has joined Nanobiotix SA as chairman of the company’s supervisory board. In this role, he will help guide the registration of the company’s product for head and neck cancer.
Dr Phillips is currently president and chief executive of OrphoMed Inc. Prior to this he was chief strategy officer at Mallinckrodt Pharmaceuticals, an American-Irish specialty pharma company. Dr Phillips earned a BA in biochemistry from the University of Pennsylvania, an MBA from the university’s Wharton School, and an MD from its School of Medicine, all in the US.
Nanobiotix announced the appointment on 25 May 2021.
Copyright 2021 Evernow Publishing Ltd